Open Journal Systems

Chidamide Combined with Paclitaxel Liposome for the Treatment of Advanced HER2-negative Breast Cancer in Clinical Study

Ichrak Ben Abdallah (Beth Israel Deaconess Medical Center, Boston, MA)
Mehmet Sitki Copur (Riga Stradiņš University, Latvia)

Abstract


The purpose of this study was to investigate the efficacy and safety of chidamide combined with paclitaxel liposome in the treatment of advanced HER-2-negative breast cancer. First, 41 patients with advanced HER-2-negative breast cancer who had received two chemotherapy regimens from May 2017 to November 2017 were randomly selected to receive chidamide combined with paclitaxel liposome treatment (observation group, n=20) or placebo combined with paclitaxel liposome treatment (control group, n=21). The treatment scheme of the observation group was oral chidamide 30mg twice a week for 2 months. In addition, on day 1, the patients were given paclitaxel liposome orally and intravenously administered with 175 mg/m2 for 1 cycle for 21 days and 3 cycles of chemotherapy. The treatment scheme of the control group was oral placebo 30 mg twice a week for 2 months. In addition, the method of paclitaxel liposome administration was the same as the observation group. The response rate (RR), disease control rate (DCR), and progression-free survival (PFS) were compared between the two groups. The results showed that all the 41 patients could be evaluated. In the observation group, CR5, PR7, SD5 and PD3 were obtained. RR was 60.0% and DCR was 85.0%. In the control group, CR3, PR3, SD5 and PD10 were obtained. RR was 28.6% and DCR was 52.4%. RR and DCR in the observation group were better than those in the control group, and the difference was statistically significant (P<0.05). The median PFS of the observation group was 5.2 months, longer than that of the control group (3.1 months, P<0.05). The main adverse reactions in the two groups were gastrointestinal reactions and bone marrow suppression, with grade 1~2 as the main ones. The incidence of leukopenia, thrombocytopenia and nausea and vomiting in the observation group was higher than that in the control group (P<0.05). Therefore, the chidamide combined with paclitaxel liposome is effective in the treatment of advanced HER-2-negative breast cancer, and the adverse reactions can be tolerated.


Keywords


Breast cancer; Negative HER⁃2 expression; Chidamide; Paclitaxel liposomes.

Full Text:

PDF

References


Zhang Z, Yang F, Yang J et al., Expression and clinical significance of PLKI and CDC20 in breast cancer. [J]. Journal of clinical oncology, 2017, 22 (7) : 622-627.

Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors[J].Eur J Med Chem, 2016(121):451-483.

Ning ZQ, Li ZB, Newman MJ, Et al. Chidemide: A new Histone deacetylase inhibitor class of the benzamide with antitumor activity and the ability to enhance immune cell mediated tumor cell toxicity [J ]. Cancer Chemother Pharmacol, 2012,69 (4):901-909.

He M, Qiao Z, Wang Y, et al. Chidemide inhibits ⁃ aerobic me tabolism to induce pancreatic cancer cell growth arrest by promo usage ⁃ ting MCL ⁃ 1 degradation [J]. PLoS One, 2016 [r].

M, Ning ZQ, Xing PY, et al. Phase I Study of Chidamide, a new Histone deacetylase inhibitor Backtients with advanced solid tumors and lymphomas [J]. Cancer Chemother Pharmacol, 2012,69 (6):1413-1422.

Shi X Q, MA Fei, LI H H, et al. Effects of cedarbenamine on apoptosis and invasion of tri-negative breast cancer cells [J]. Journal of clinical oncology, 2013,18 (12): 1057-1059.

Xiang D, Jiang Z, Gu X Y, et al. Antiproliferative effect of sidalamine combined with cisplatin on MDA⁃MB 231 cell lines and its mechanism in vitro [J]. Journal of southeast university (medical edition), 2013,32 (3):283-287.

Del B D, Desideri M, De L T, Et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non⁃small cell lung cancer [J]. Mol, cancer, 25301686.

Zheng H, Zhao W, Yan C, et al. HDAC inhibitors enhance T cell chemokine expression and augment response to 1 immune of PD adenocarcinoma[J].Clin Cancer Res, 2016,22 (16):4119-4132.

Chen YP. Research progress of regulation of tri-negative breast cancer and histone deacetylation [J]. Journal of applied oncology, 2011,25 (3):287-288.

Nie J Y, Chen Y P, HUANG Y C, et al. Effect of histone deacetylase inhibitor and combined chemotherapy on proliferation of breast cancer cells [J]. Chinese journal of clinical oncology, 2011,38 (4):189-191.



DOI: http://dx.doi.org/10.30564/amor.v5i5.255

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Ichrak Ben Abdallah, Mehmet Sitki Copur

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.